STANFORD FIVE CITY MULTIFACTOR RISK REDUCTION STUDY

斯坦福大学五城多因素降低风险项目是一项长期的 社区卫生服务的可行性和有效性的现场研究 旨在降低心血管疾病(CVD)风险的教育， 发病率和死亡率。该项目始于1978年，历时六年 教育工作于1986年完成。风险因素的变化由两个因素衡量 一系列具有代表性的人口抽样调查，一系列调查 关于独立样本，另一个是关于队列的一系列调查 样本。这两个系列的调查都在1990年完成。发病率和 死亡率是通过医院的社区监测系统来衡量的 记录和死亡证明，这一点仍在继续。当前资金到期日 1992年6月。 提议的竞争性延续的目的是：1)扩展 三年内的发病率和死亡率监测(至1994年6月 截至1992年12月的活动)；2)延长《框架公约》的分析和出版 结果和方法；3)提供少量的增量 支持使用早期FCP人群的冷冻血浆样本 对高密度脂蛋白相关性进行嵌套式病例对照研究的调查 亚组分和载脂蛋白与致命性和非致命性心血管疾病 疾病。需要扩大监控数据收集范围，以确保 检测重大风险对发病率和死亡率的任何影响 与对照相比，治疗城市中发生的因素变化 城市，到1986年。许多潜在的分析将不可能在 目前的供资水平和期限，特别是涉及 干预计划的组成部分，其中的数据集非常原始， 和过程评估。嵌套病例对照研究将涉及 将调查和监视数据集进行匹配，以识别患有 记录了参与五项人口调查之一的事件， 确定并联系潜在的控制措施，以确保它们是 不含心血管疾病，并分析-80度冰冻的血浆样品 载脂蛋白A-I和B以及HDL2，3亚组分的摄氏度。这 将允许对这些因素之间的关联进行多因素评估 以及在许多其他变量已知的人中发生心血管疾病。

The Stanford Five-City Multifactor Risk Reduction Project is a long-term field study of the feasibility and effectiveness of community health education directed at lowering cardiovascular disease (CVD) risk, morbidity, and mortality. The Project began in 1978 and six years of education were completed in 1986. Risk factor change is measured by two series of representative population sample surveys, one a series of surveys on independent samples and the other a series of surveys on a cohort sample. Both series of surveys were completed in 1990. Morbidity and mortality are measured by a system of community surveillance of hospital records and death certificates, which is continuing. Current funding ends in June 1992. The purpose of the proposed competitive continuation is to 1) extend morbidity and mortality surveillance by three years (to June 1994 for events through December 1992); 2) to extend analysis and publication of FCP results and methods; and 3) to provide a small amount of incremental support to enable use of frozen plasma samples from earlier FCP population surveys to conduct a nested case-control study of the association of HDL subfractions and apolipoproteins with fatal and non-fatal cardiovascular disease. Extension of surveillance data collection is needed to insure the detection of any impact on morbidity and mortality of the significant risk factor changes that occurred in the treatment cities, compared to control cities, by 1986. Many potential analyses will not be possible within the current funding levels and duration, particularly those involving components of the intervention program, where the data sets are quite raw, and process evaluation. The nested case-control study will involve matching the survey and surveillance data sets to identify persons with documented events who participated in one of the five population surveys, identifying and contacting potential controls to be certain that they are free of CVD, and analysis of plasma samples frozen at -80 degrees centigrade for apolipoproteins A-I and B and HDL2,3 subfractions. This will allow multifactor assessment of the association between those factors and CVD in persons for whom many other variables are known.